Search
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalNedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalAsparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia
Products: LEUNASE FOR INJECTION 10,000 iu/vial, LEUNASE ENJEKTABL 10.000 IU FLAKON, 1 ADETOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesAGS-16C3F
go.drugbank.com/drugs/DB17551InvestigationalAGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate.
EGT-101
go.drugbank.com/drugs/DB17645ExperimentalEGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalSponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].
Tezosentan
go.drugbank.com/drugs/DB06558InvestigationalTezosentan is an intravenous endothelin receptor A/B antagonist.
Talacotuzumab
go.drugbank.com/drugs/DB14796InvestigationalTalacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
go.drugbank.com/drugs/DB16520ExperimentalCOVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen